Business
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosc...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal\nCanada NewsWire\nCALGARY, Jan 25, 2016\n\n\n\nCALGARY, Jan 25, 2016 /CNW/ - Resverlogix Corp. (the \"Corporation\") (TSX:RVX) today announced the acceptance for publication of a manuscript titled: \"RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease,\" in the journal \"Atherosclerosis\". \n\nThe key information in the manuscript details some of the beneficial actions of apabetalone (RVX-208), a bromodomain extra-terminal (BET) protein inhibitor for treating high-risk cardiovascular disease (CVD) patients. The data presented emphasises not only that apabetalone (RVX-208) raises the levels of ApoA-I and HDL, but also that the epigenetic actions of this BET inhibitor can modulate several factors known to be major contributors to CVD risk.  \n\nDr. Norman C.W. Wong, chief scientific officer of Resverlogix stated, \"We are pleased to have our data peer reviewed and published in the Atherosclerosis journal. This additional recognition helps to further confirm the importance of epigenetics in successfully modulating key CVD pathways.\"         \n\nThe accepted manuscript is currently in electronic press and will appear in a future print issue of Atherosclerosis. An online version of the manuscript can be accessed at: http://www.atherosclerosis-journal.com/article/S0021-9150(16)30035-1/fulltext \n\nAbout Resverlogix\n\nResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within th...